3-[(2S,4S,6S)-4-(5-fluoro-3,4-dihydro-2,4-dioxopyrimidin-1(2H)-yl)-6-(hydroxymethyl)-2-methyltetrahydrofuro[3,4-d] [1,3]dioxol-2-yl]propanoic acid | 1502809-75-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪类
• 英文名称: 3-[(2S,4S,6S)-4-(5-fluoro-3,4-dihydro-2,4-dioxopyrimidin-1(2H)-yl)-6-(hydroxymethyl)-2-methyltetrahydrofuro[3,4-d] [1,3]dioxol-2-yl]propanoic acid
• 英文别名: 3-[4-(5-fluoro-2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)-6-(hydroxymethyl)-2-methyltetrahydrofuro[3,4-d][1,3]dioxol-2-yl]propanoic acid；3-((2R,3aR,4R,6R,6aR)-4-(-3,4-dihydro-5-fluoro-2,4-dioxopyrimidin-1(2H)-yl)-6-(hydroxymethyl)-2-methyltetrahydrofuro[3,4-d] [1,3]dioxol-2-yl)propanoic acid
• CAS: 1502809-75-7
• 化学式: C₁₄H₁₇FN₂O₈
• 分子量: 360.296
• InChiKey: JSKVYSHIRKRKAE-WEUFEVMQSA-N

物化性质

• 密度：
  1.61±0.1 g/cm3(Temp: 20 °C; Press: 760 Torr)(predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  -1.07
• 重原子数：
  25.0
• 可旋转键数：
  5.0
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.64
• 拓扑面积：
  140.08
• 氢给体数：
  3.0
• 氢受体数：
  8.0

反应信息

• 作为产物：
  描述：

  ethyl 3-[(2R,3aR,4R,6R,6aR)-4-(3,4-dihydro-5-fluoro-2,4-dioxopyrimidin-1(2H)-yl)-6-(hydroxymethyl)-2-methyltetrahydrofuro[3,4-d] [1,3]dioxol-2-yl]propanoate 在 水 、 sodium hydroxide 作用下， 以 乙醇 为溶剂， 反应 0.5h， 以82%的产率得到3-[(2S,4S,6S)-4-(5-fluoro-3,4-dihydro-2,4-dioxopyrimidin-1(2H)-yl)-6-(hydroxymethyl)-2-methyltetrahydrofuro[3,4-d] [1,3]dioxol-2-yl]propanoic acid
  参考文献：
  名称：

  5-氟尿苷在壳聚糖上的固定化

  摘要：

  合成了抑制癌的 5-氟尿苷的 2',3'-O-乙酰丙酸衍生物 2b 及其 N(3)-法呢基化核脂 2d，并与不同分子量和不同 pH 值的 H2O 可溶性壳聚糖偶联。 3.5-5.5) 导致 6 和 7。此外，香豆素荧光团 ATTO-488 N(9)-丁酸酯通过顺序偶联技术与生物聚合物结合，得到 9 和 10。此外，制备壳聚糖箔，以其中 2b 是耦合的。在 Franz 扩散池中用紫外分光光度法研究壳聚糖酶（来自 Streptomyces sp. N174）对它们的降解。

  DOI：

  10.1002/cbdv.201300025

文献信息

• 5-Fluoruoracil Derivatives
  申请人：B. Braun Melsungen AG

  公开号：EP2712868A1

  公开（公告）日：2014-04-02

  The present invention relates to a compound represented by formula (I) wherein X is selected from the group of formulae (II) to (IV) wherein R1 is H or C1-C50 chain which may be branched or linear and which may be saturated or unsaturated and which may optionally be interrupted and/or substituted by one or more hetero atom(s) (Het1) and/or functional group(s)(G1); or R1 is a C3-C28 moiety which comprises at least one cyclic structure and which may be saturated or unsaturated and which may optionally be interrupted and/or substituted by one or more hetero atom(s) (Het1) and functional group(s)(G1); R2 is H; or R2 is a Mono-phosphate, Di-phosphate, Tri-phosphate or phosphoramidite moiety; or R2 is -Y-X or -Y-L-Y1- X; Y and Y1 are independently from each other a single bond or a functional connecting moiety, X is a colloid-active compound (CA) or a fluorescence marker (FA) or a polynucleotide moiety having up to 50 nucleotide residues, preferably 10 to 25 nucleotides, especially a polynucleotide having an antisense or antigen effect; L is a linker by means of which Y and X are covalently linked together; R3 and R4 represent independently from each other a C1-C28-alkyl moiety which may optionally be substituted or interrupted by one or more heteroatom(s) and/or functional group(s);or R3 and R4 form a ring having at least 5 members, preferably a ring having 5 to 8 carbon atoms and wherein the ring may be substituted or interrupted by one or more hetero atom(s) and/or functional group(s); or R3 and R4 represent independently from each other a C1-C28-alkyl moiety substituted with one or more moieties selected from the group -Y-X or -Y-L-Y1-X; or R3 and R4 represent independently from each other -Y-X or -Y-L-Y1- X; R5 and R6 represent independently from each other a C1-C28-alkyl moiety which may optionally be substituted or interrupted by one or more heteroatom(s) and/or functional group(s); or R5 and R6 represent independently from each other a C1-C28-alkyl moiety substituted with one or more moieties selected from the group -Y-X or -Y-L-Y1-X; or R5 and R6 form a ring having at least 5 members, preferably a ring having 5 to 18 carbon atoms and wherein the ring may be substituted or interrupted by one or more hetero atom(s) and/or functional group(s); and/or one or more moieties selected from the group -Y-X or -Y-L-Y1- X; R5 and R6 represent independently from each other -Y-X or -Y-L-Y1- X; R7 is a hydrogen atom or -O-R8; R8 is H or C1-C28 chain which may be branched or linear and which may be saturated or unsaturated and which may optionally be interrupted and/or substituted by one or more hetero atom(s) (Het1) and/or functional group(s)(G1); or R8 is -Y-X or -Y-L-Y1- X, with the proviso that R1 and R2 are not both H and/or with the proviso that the compound comprises at least two chains each of which having 4 or more carbon atoms.

  本发明涉及一种由以下公式（I）表示的化合物，其中X选自以下公式（II）至（IV）中的一种：其中R1为H或C1-C50链，可以是支链或直链，可以是饱和或不饱和，并且可能被一个或多个杂原子（Het1）和/或功能基团（G1）中断和/或取代；或R1为包含至少一个环结构的C3-C28基团，可以是饱和或不饱和，并且可能被一个或多个杂原子（Het1）和功能基团（G1）中断和/或取代；R2为H；或R2为单磷酸酯、双磷酸酯、三磷酸酯或磷酰胺基团；或R2为-Y-X或-Y-L-Y1-X；Y和Y1分别独立地为单键或功能连接基团；X为胶体活性化合物（CA）或荧光标记物（FA）或具有最多50个核苷酸残基的多核苷酸基团，优选为10至25个核苷酸，特别是具有反义或抗原效应的多核苷酸；L为连接剂，用于将Y和X共价连接在一起；R3和R4分别独立地表示可以选择性地被一个或多个杂原子和/或功能基团取代或中断的C1-C28烷基基团；或R3和R4形成具有至少5个成员的环，优选为具有5至8个碳原子的环，并且该环可以被一个或多个杂原子和/或功能基团取代或中断；或R3和R4分别独立地表示用一个或多个从-Y-X或-Y-L-Y1-X中选择的基团取代的C1-C28烷基基团；或R3和R4分别独立地表示-Y-X或-Y-L-Y1-X；R5和R6分别独立地表示可以选择性地被一个或多个杂原子和/或功能基团取代或中断的C1-C28烷基基团；或R5和R6分别独立地表示用一个或多个从-Y-X或-Y-L-Y1-X中选择的基团取代的C1-C28烷基基团；或R5和R6形成具有至少5个成员的环，优选为具有5至18个碳原子的环，并且该环可以被一个或多个杂原子和/或功能基团取代或中断；和/或一个或多个从-Y-X或-Y-L-Y1-X中选择的基团；R5和R6分别独立地表示-Y-X或-Y-L-Y1-X；R7为氢原子或-O-R8；R8为H或C1-C28链，可以是支链或直链，可以是饱和或不饱和，并且可能被一个或多个杂原子（Het1）和/或功能基团（G1）中断和/或取代；或R8为-Y-X或-Y-L-Y1-X，但R1和R2不能同时为H，且化合物至少包含两条每条至少有4个或更多碳原子的链。